Jerry Lee, MD, MPhil, MS

Assistant Professor, Hematology/Oncology @UCSF || Myeloid Disorders - Acute Leukemia, Histiocytic Neoplasms, HLH/Hyperinflammation, BMT/Cell Tx || 🐶 Enthusiast

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

This is always the best ending to an otherwise tough year. Be good to each other, kind to ourselves, and remember to live life fully with all the love in the world.

[WeRateDogs @dog_rates]

The Dogs of 2025 ❤️ please enjoy

https://t.co/hScyIMIVPl

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

The best

[WeRateDogs @dog_rates]

The Dogs of 2024

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

🤔 https://t.co/Dt7lUjxTNQ

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

Will be the first of many... https://t.co/zYB0xVnbc7

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

Obe-cel approved for R/R ALL, with an encouraging comparative toxicity profile - will see with real-world data. What we do know already is that this is already the most dinosaur-sounding CAR T - "Aucatzyl" https://t.co/GrSCnmeHOb

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

@Aetna I just sent a secured message back to your email. Hopefully Aetna can authorize it after a third try

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

First time getting a drug denied by insurance (@Aetna): I've learned that Medicare-approved journals for coverage include Lancet and Lancet Oncology, but not @TheLancetHaem. Go figure

[Corynn Kasap @corynnkasap]

Check out our new CAR-T target for high-risk myeloma! In our pre-print we show that CD70 is a novel CAR-T target expressed in high-risk MM subtypes, and leverage CD70's natural ligand (CD27) to design a CAR-T with enhanced in vivo expansion. See the full thread below!

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

Chargers have finally made a smart move!!

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

My favorite Twitter re-share each year

[WeRateDogs @dog_rates]

The Dogs of 2023

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

Ridiculous, let's just not play any games. Terrible for FSU fans, coaches, and players

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

A lot of SEC bias in the media, which has always been the case, but I don't see the committee dropping an undefeated P5 champ. The bigger question would've been which one-loss team gets in, but luckily for the committee, it's already decided based on head-to-head. Sorry SEC

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

@dog_rates Rarest of all, 16/10

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

@drkomanduri I can't decide which of the yes to select 🙃

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

Also:
"It was particularly horrible as that same week, I had just been diagnosed with cancer...I was facing two operations, and my husband, who had gone back to Hungary to pick up his green card...I was really struggling, and then they told me this.”

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

A reminder: “They told me [Katalin Kariko] that they’d had a meeting and concluded that I was not of faculty quality,” she said. ”When I told them I was leaving, they laughed at me and said, ‘BioNTech doesn’t even have a website.’” https://t.co/wmqGMFM30s

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

wat 🤨

[The Boston Globe @BostonGlobe]

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center have announced plans to build a new inpatient hospital for adult cancer care in Boston, breaking the cancer hospital’s almost 30-year relationship with Brigham and Women’s. https://t.co/bTUGRdQ7hM

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

@NikeshanJ Mind/heart/stomach/liver**

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

Zero expectations coming in - now leaving with academic BFFs, a cadre of mentors, #TeamMultilevel and a completely full mind/heart. Cannot recommend enough. Thank you #ASHCRTI for an incredible, enriching experience!

[Jerry Lee, MD, MPhil, MS @TheBloodDoc]

@KellyNFitz Congrats and welcome back!! Hope to see you soon =)